SCHEMBL7126911

SCHEMBL7126911

Cc1[nH]c(C=O)c(C)c1CC(=O)NCC1CCN(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
KDR P35968 1/20 0.42
KCNH2 Q12809 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
NPC1 O15118 2/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
RAB9A P51151 1/20 0.36
CNR2 P34972 2/20 0.35
MAPT P10636 1/20 0.34
PARP1 P09874 1/20 0.34
GSK3B P49841 2/20 0.33
NAMPT P43490 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401668 0.76 L3MBTL1 (0.45) PDGFRBFGFR1KDRNPC1ALDH1A1
SCHEMBL7126930 0.74 LMNA (0.40) PDGFRBFGFR1KDRMAPTALDH1A1
SCHEMBL5410132 0.74 POLB (0.53) PDGFRBFGFR1KDRALDH1A1
SCHEMBL7114605 0.73 TSHR (0.35)
SCHEMBL7128957 0.70 ALDH1A1 (0.34) NPC1MAPTALDH1A1HTT
SCHEMBL5405508 0.68 KDR (0.41) PDGFRBFGFR1KDRKCNH2ACHE
SCHEMBL12964152 0.68 CKS1B (0.46) KCNH2CACNA1IMAPTGSK3BNAMPT
SCHEMBL5401557 0.68 KDM4E (0.44) PDGFRBFGFR1KDRRAB9AMAPT
SCHEMBL1313872 0.67 KDM1A (0.42) PDGFRBFGFR1KDRALDH1A1
SCHEMBL16494745 0.67 CYP2D6 (0.50) MAPTGSK3BNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 PDGFRB 348/4885FGFR1 637/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.